Recursion Pharmaceuticals, Inc.
RXRX
$6.35
$0.416.90%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -82.57% | 80.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -82.57% | 80.91% | |||
| Cost of Revenue | 28.21% | 4.27% | |||
| Gross Profit | -75.89% | 11.81% | |||
| SG&A Expenses | 104.71% | 18.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 51.42% | 8.24% | |||
| Operating Income | -86.95% | 2.18% | |||
| Income Before Tax | -86.99% | 2.44% | |||
| Income Tax Expenses | -95.81% | 131.93% | |||
| Earnings from Continuing Operations | -86.67% | 1.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -86.67% | 1.74% | |||
| EBIT | -86.95% | 2.18% | |||
| EBITDA | -87.51% | 0.46% | |||
| EPS Basic | -56.96% | 15.77% | |||
| Normalized Basic EPS | -57.33% | 16.40% | |||
| EPS Diluted | -57.38% | 15.57% | |||
| Normalized Diluted EPS | -57.33% | 16.40% | |||
| Average Basic Shares Outstanding | 18.92% | 16.68% | |||
| Average Diluted Shares Outstanding | 18.92% | 16.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
